Investigating factors affecting PD-L1 testing in cancer patients
Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients
This study is working on a new test to better measure a protein called PD-L1 in cancer tissues, which helps doctors find out if certain patients might benefit from immunotherapy, using small samples from biopsies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11000384 on NIH RePORTER |
What this research studies
This research focuses on improving the accuracy of predictive biomarker assays for PD-L1 protein expression in tumor tissues, which is crucial for identifying cancer patients who may benefit from immunotherapy. The study aims to develop a multiplexed immunohistochemical assay that can assess PD-L1 alongside other tissue markers from small biopsy samples. By examining patient-specific factors and pre-analytical variables that may influence test results, the research seeks to enhance the reliability of PD-L1 testing, which is vital for effective cancer treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with malignancies such as melanoma, lung cancer, bladder cancer, or gastroesophageal cancer who are undergoing PD-L1 testing.
Not a fit: Patients with cancers not associated with PD-L1 testing or those who are not candidates for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate identification of patients who are likely to respond to immunotherapy, improving treatment outcomes.
How similar studies have performed: Previous research has shown promise in improving biomarker assays for cancer therapies, indicating that this approach could yield significant advancements.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Roehrl, Michael H. a. — Beth Israel Deaconess Medical Center
- Study coordinator: Roehrl, Michael H. a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.